STRS Ohio’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$9.83M Buy
30,140
+1,323
+5% +$431K 0.04% 398
2025
Q1
$7.78M Buy
28,817
+3,817
+15% +$1.03M 0.03% 418
2024
Q4
$5.88M Sell
25,000
-4,468
-15% -$1.05M 0.02% 469
2024
Q3
$8.1M Buy
29,468
+4,468
+18% +$1.23M 0.03% 413
2024
Q2
$6.08M Hold
25,000
0.02% 438
2024
Q1
$3.74M Hold
25,000
0.01% 502
2023
Q4
$4.79M Hold
25,000
0.02% 461
2023
Q3
$4.43M Sell
25,000
-5,000
-17% -$885K 0.02% 471
2023
Q2
$5.7M Buy
30,000
+25,472
+563% +$4.84M 0.02% 458
2023
Q1
$907K Buy
4,528
+905
+25% +$181K ﹤0.01% 983
2022
Q4
$861K Buy
3,623
+312
+9% +$74.1K ﹤0.01% 1000
2022
Q3
$662K Buy
+3,311
New +$662K ﹤0.01% 1149
2022
Q2
Sell
-5,291
Closed -$863K 2040
2022
Q1
$863K Buy
5,291
+4,000
+310% +$652K ﹤0.01% 1126
2021
Q4
$218K Hold
1,291
﹤0.01% 1710
2021
Q3
$243K Hold
1,291
﹤0.01% 1719
2021
Q2
$218K Sell
1,291
-3,029
-70% -$511K ﹤0.01% 1797
2021
Q1
$609K Sell
4,320
-150
-3% -$21.1K ﹤0.01% 1488
2020
Q4
$580K Sell
4,470
-7,069
-61% -$917K ﹤0.01% 1390
2020
Q3
$1.68M Sell
11,539
-409
-3% -$59.5K 0.01% 694
2020
Q2
$1.77M Buy
11,948
+8,046
+206% +$1.19M 0.01% 659
2020
Q1
$424K Buy
3,902
+2,835
+266% +$308K ﹤0.01% 1248
2019
Q4
$122K Hold
1,067
﹤0.01% 1750
2019
Q3
$85K Hold
1,067
﹤0.01% 1789
2019
Q2
$77K Hold
1,067
﹤0.01% 1856
2019
Q1
$99K Sell
1,067
-3,115
-74% -$289K ﹤0.01% 1792
2018
Q4
$304K Hold
4,182
﹤0.01% 1503
2018
Q3
$366K Hold
4,182
﹤0.01% 1521
2018
Q2
$411K Buy
4,182
+3,100
+287% +$305K ﹤0.01% 1468
2018
Q1
$128K Sell
1,082
-35
-3% -$4.14K ﹤0.01% 1550
2017
Q4
$141K Buy
+1,117
New +$141K ﹤0.01% 1552
2016
Q2
Sell
-1,699
Closed -$106K 1915
2016
Q1
$106K Buy
1,699
+105
+7% +$6.55K ﹤0.01% 1648
2015
Q4
$150K Buy
1,594
+192
+14% +$18.1K ﹤0.01% 1578
2015
Q3
$112K Buy
+1,402
New +$112K ﹤0.01% 1638
2014
Q2
Sell
-13,600
Closed -$913K 1694
2014
Q1
$913K Hold
13,600
﹤0.01% 786
2013
Q4
$875K Sell
13,600
-1,600
-11% -$103K ﹤0.01% 837
2013
Q3
$973K Buy
15,200
+10,500
+223% +$672K ﹤0.01% 847
2013
Q2
$146K Buy
+4,700
New +$146K ﹤0.01% 1564